Efficacy and tolerability of oxcarbazepine in the treatment of focal epilepsy in neonates and infants under 3 months of age: A single-center retrospective analysis

• DOI: 10.1016/j.eplepsyres.2023.107240
• Publication Date: 2023-10-12T15:58:45Z
• Authors: Yuping Ma; Jie Deng; Zhengran Fu; Chunhong Chen; Xiaohui Wang; Xu Wang; Jingwen Weng; Yanhua Shen; Xiaoling Wang; Fang Fang
• Keywords: Oxcarbazepine; Tolerability; Epileptic spasms; Epilepsy in children; Sodium channel blocker; Epilepsy syndromes

The neonatal and infantile period is the age group with highest incidence of epilepsy, in which gene variants sodium potassium channels are an important etiology, so channel blocker class antiseizure medications may be effective treatment early onset epilepsy. This study aimed to summarize efficacy tolerability oxcarbazepine (OXC) focal epilepsy neonates infants under 3 months age.A retrospective analysis children within treated OXC a tertiary pediatric center China was conducted. efficacy, influencing factors were evaluated.A total 50 patients enrolled, median 11.5 (2, 42) days. There 32 cases developmental epileptic encephalopathy, 10 self-limited or neonatal-infantile 8 that could not classified as syndrome. application 47 (31, 66) follow-up time 16.5 (10, 25) months, 7 deaths. Thirty-eight (76.0 %) treatment, including 28 (56.0 achieved seizure freedom. Of 34 whose pathogenesis involved genetic factors, 19 sodium/ had higher seizure-free rates than those other variants. most common adverse event transient hyponatremia. 2 rash abnormal electrocardiogram, discontinued OXC.This single-center suggests tolerable for age. better